期刊文献+

人工泪液对局部应用抗青光眼药物造成眼表损伤的预防作用 被引量:10

Preventive effect of artificial tears on ocular surface damage due to anti-glaucoma medicine
下载PDF
导出
摘要 目的探讨人工泪液对局部应用抗青光眼药物造成眼表损伤的预防作用。方法选取已确诊为原发性开角型青光眼并需局部应用抗青光眼药物治疗的患者50例(50眼),随机分为观察组与对照组,各25例(25眼),对照组患者只给予抗青光眼药物治疗,观察组患者给予抗青光眼药物与人工泪液治疗,并于治疗前及治疗3个月后对所有观察对象行眼压测量、泪膜破裂时间(break-up time,BUT)、SchirmerⅠ试验(SchirmerⅠtest,SⅠt)及角膜荧光素钠染色评分检查。结果对照组与观察组治疗后眼压分别为(17.00±2.10)mm Hg(1k Pa=7.5mm Hg)和(16.72±2.28)mm Hg,都明显低于治疗前的(33.56±4.09)mm Hg和(33.72±3.98)mm Hg,差异均有统计学意义(均为P=0.000)。对照组治疗3个月后BUT(6.44±1.76)s较治疗前(9.92±1.99)s明显缩短,差异有统计学意义(t=5.618,P=0.000);观察组治疗后BUT与治疗前相比,差异无统计学意义(P>0.05);对照组治疗3个月后BUT较观察组(9.00±1.53)s明显缩短,差异有统计学意义(t=-6.462,P=0.000)。对照组以及观察组治疗前后SⅠt比较差异均无统计学意义(均为P>0.05);治疗3个月后,两组间SⅠt比较差异无统计学意义(P>0.05)。对照组角膜荧光素钠染色评分治疗后为(3.08±1.35)较治疗前(0.88±0.73)明显增加,差异有统计学意义(t=-8.124,P=0.000);观察组治疗后与治疗前相比,差异无统计学意义(P>0.05);治疗3个月后对照组角膜荧光素钠染色评分(3.08±1.35)较观察组(1.00±0.58)明显增加,差异有统计学意义(t=7.525,P=0.000)。结论人工泪液可减轻局部应用抗青光眼药物所造成的眼表损害,有一定的预防作用,同时对抗青光眼药物疗效无明显影响。 Objective To observe the preventive effect of artificial tears on ocular surface damage due to anti-glaucoma medicine. Methods All 50 patients( 50eyes) with primary open angle glaucoma and local anti-glaucoma drugs were selected and randomly divided into observation group and control group,25 patients in each group,the patients in control group were only given anti-glaucoma medicine,the observation group given anti-glaucoma medicine and artificial tears. All patients were evaluated intraocular pressure( IOP),tear break-up time( BU T),Schirmer I test( SIt),and corneal fluorescein staining( FL) before treatment and 3 months after treatment.Results The IOP after treatment of control group and observation group( 17. 00 ± 2. 10) mmHg( 1 k Pa = 7. 5 mm Hg) and( 16. 72 ± 2. 28) mm Hg,respectively,were significantly low er than before treatment( 33. 56 ± 4. 09) mm Hg and( 33. 72 ± 3. 98) mm Hg,the differences were statistically significant( all P = 0. 000). BU Tin the control group after treatment was( 6. 44 ± 1.76) seconds,shorter than before treatment( 9. 92 ± 1. 99) seconds,the difference was statistically significant( t = 5. 618,P = 0. 000); In the observation group the difference was not statistically significant( P 〉 0. 05); After 3 months of treatment,the control group( 6. 44 ± 1. 76) seconds was significantly shorter than that of the observation group( 9. 00 ± 1. 53) seconds,the difference was statistically significant( t =- 6. 462,P = 0. 000). The difference in SIt results before and after treatment in the control group and observation group was not statistically significant( all P 〉 0.05); After 3 months of treatment,there was no significant difference between the two groups( P〉 0. 05). FL score in the control group after treatment( 3. 08 ± 1. 35) was higher than before treatment( 0. 88 ± 0. 73) significantly,the difference was statistically significant( t =- 8. 124,P = 0. 000); The difference before and after treatment in the observation group was not statistically significant( P 〉 0. 05); After 3 months of treatment,the control group( 3. 08 ± 1.35) was significantly increased compared with the observation group( 1. 00 ± 0. 58),and the difference was statistically significant( t = 7.525,P = 0. 000). Conclusion The artificial tears can reduce the ocular surface damage due to long-term use of topical anti-glaucoma medicine,and there is a certain preventive effect with no obvious effect on the efficacy of anti-glaucoma medicine.
出处 《眼科新进展》 CAS 北大核心 2016年第7期671-673,共3页 Recent Advances in Ophthalmology
关键词 人工泪液 抗青光眼药物 眼表损伤 artificial tears anti-glaucoma medicine ocular surface damage
  • 相关文献

参考文献13

  • 1GARCIA-FEUOO J,SAMPAOLSI JR.A multicenter evaluation of ocular suurface diseaseprevalence in patients with glauco- ma[J].Clin Ophthalmol,2012,6:441-446.
  • 2AYAKI M,IWASAWA A,INOUE Y.Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human comeal endotjelial cell[J].Clin Ophthalmol,2010,4:1217-1222.
  • 3HAMARD P,BLONDIN C,DEBBASCH C,WARNET JM,BAU- DOUIN C ,BRIGNOLE F.In vitro effects of preserved and un- preserved antiglaucoma drugs on apoptotic marker expres- sion by human trabecular cells[J].Graefes Arch Clin Eocp Ophthalmol,2003,241(12):1037-1043.
  • 4MANNI G,CENTOANTI M,ODDONE F,PARRAVANO M,BUCCI MG.Interleukin-Ibeta tear concentration in glaucomatous and ocular hypertensive patients treated with preservative-free nonselective beta-blockers[J].Am J Ophthalmol,2005,139(1).72-77.
  • 5陶远,刘英.不含苯扎氯铵的曲伏前列素滴眼液对患者干眼症状及泪膜质量的影响[J].眼科,2015,24(3):153-155. 被引量:7
  • 6IHAN A,CVENKEL B.Conjunctival epithelium expression of HLA-DR in glaucoma patients and its influence on the out- come of filitration surgery[J].Br J Ophthalmol,2000,84(6):648-650.
  • 7SHIMAZAKI J,HANANDA K,YAGI Y,YAMAGAMI J,ISHIOKA M,SHIMMURA S,et al.Changes in ocuiar surface caused by antiglauematous eyedrops :prospective,randomlsd study for the comparison of 0.5% timololvO.12% unoprostone[J].Br J Ophthalmol,2000,84(11):1250-1254.
  • 8麻南,胡莲娜,高付林.不含苯扎氯铵的抗青光眼滴眼液疗效及安全性的Meta分析[J].眼科,2011,20(4):283-286. 被引量:4
  • 9GUILLON M,MAISSA C,POUUQUEN P,DELVAL L.Effect of povidone 2% preservative-free eyedrops on contact lens wearers with computer visual syndrome:pilot study[J].Eye Contact Lens,2004,30(1):34-39.
  • 10VERSURA P,PROFAZIP V,CAMPOS EC.One month use of Systane improvesocular surface parameters in subieets with moderate symptoms of oculardiyness[J].Clin Ophthalmol,2008,2(3):629-635.

二级参考文献34

  • 1李学民,张君,王薇.泪道栓塞术治疗干眼症的临床效果[J].中华眼科杂志,2005,41(12):1098-1102. 被引量:41
  • 2樊天觉.角膜异物剔除术后使用贝复舒滴眼液的疗效观察[J].临床眼科杂志,2006,14(3):252-253. 被引量:6
  • 3Ayaki M, Iwasawa A, Inoue Y. Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells. Clin Ophthalmol, 2010, 4: 1217-1222.
  • 4Hamard P, Blondin C, Debbasch C, et al. In vitro effects of preserved and unpreserved antiglaucoma drugs on apoptotic marker expression by human trahecular ceils. Graefes Arch Clin Exp Ophthalmol, 2003, 241: 1037-1043.
  • 5Manni G, Centofanti M, Oddone F, et al. Interleukin-lheta tear eoncentration in glaueomatous and ocular hypertensive patients treated with preservative-free nonseleetive beta-bloekers. Am J Ophthalmol, 2005, 139: 72-77.
  • 6Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials, 1996, 17: 1-12.
  • 7Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma, 2002, 11: 119-126.
  • 8Mundorf T, Williams R, Whitcup S, et al. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Oeul Pharmaeol Ther, 2003, 19: 37-44.
  • 9Lewis RA, Katz GJ, Weiss MJ, et al. Travoprost 0.004% with and without beuzalkonium chloride: a comparison of safety and efficacy. J Glaucoma, 2007, 16: 98-103.
  • 10Hamacher T, Airaksinen J, Saarela V, et al. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol, 2008, 86 (Suppl 242): 14-19.

同被引文献99

引证文献10

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部